Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIRALL
2024-514345-11-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Safety: absence of limiting toxicities between infusion and Day 28 and Efficacy at Month 3: MRD-negative complete remission and B-cell aplasia. Planned start Aug 2024; status: authorised.
02
Drugs
nivolumabtisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2024-514345-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514345-11-00.